Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report.
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
27
06
2020
revised:
29
07
2020
accepted:
11
08
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID-19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.
Identifiants
pubmed: 33363865
doi: 10.1002/ccr3.3307
pii: CCR33307
pmc: PMC7752410
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2990-2994Informations de copyright
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors disclose no potential financial or nonfinancial conflict of interests.
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
Lancet Respir Med. 2020 Apr;8(4):e18
pubmed: 32145829
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
World Acad Sci J. 2020 May;2(3):
pubmed: 32313883
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Rheumatology (Oxford). 2020 Sep 1;59(9):2287-2298
pubmed: 31846042
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1124-1125
pubmed: 32317036
ACR Open Rheumatol. 2020 May;2(5):276-282
pubmed: 32267081
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282